Girish Mahajan (Editor)

Vascular targeting agent

Updated on
Edit
Like
Comment
Share on FacebookTweet on TwitterShare on LinkedInShare on Reddit

A vascular-targeting agent (VTA) or vascular disrupting agent (VDA) is a drug designed to damage the vasculature (blood vessels) of cancer tumors causing central necrosis.

VTAs can be small-molecule or ligand-based.

Small-molecule VTAs include:

  • microtubule destabilizing drugs such as combretastatin A-4 disodium phosphate (CA4P), ZD6126, AVE8062, Oxi 4503
  • vadimezan (ASA404)

    • Clinical trials

    Phase II : ZD6126, CA4P, plinabulin (NPI-2358)

    Phase III : DMXAA (ASA404).

    References

    Vascular-targeting agent Wikipedia
    (Text) CC BY-SA